119 related articles for article (PubMed ID: 38621338)
1. Design, synthesis, and biological evaluation of cathepsin B cleavage albumin-binding SN38 prodrug in breast cancer.
Lu Y; Huang Y; Jin J; Yu J; Lu W; Zhu S
Bioorg Chem; 2024 Jun; 147():107370. PubMed ID: 38621338
[TBL] [Abstract][Full Text] [Related]
2. Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution.
Wei Q; Wu Y; Jiang X; Lu W; Liu S; Yu J
Bioorg Med Chem; 2024 May; 106():117754. PubMed ID: 38728869
[TBL] [Abstract][Full Text] [Related]
3. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
4. A camptothecin-based, albumin-binding prodrug enhances efficacy and safety in vivo.
Cheng Z; Huang Y; Shen Q; Zhao Y; Wang L; Yu J; Lu W
Eur J Med Chem; 2021 Dec; 226():113851. PubMed ID: 34547508
[TBL] [Abstract][Full Text] [Related]
5. "Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy.
Ding N; Xu S; Zheng S; Ye Q; Xu L; Ling S; Xie S; Chen W; Zhang Z; Xue M; Lin Z; Xu X; Wang L
J Mater Chem B; 2021 Mar; 9(12):2816-2830. PubMed ID: 33690741
[TBL] [Abstract][Full Text] [Related]
6. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib.
Karnthaler-Benbakka C; Koblmüller B; Mathuber M; Holste K; Berger W; Heffeter P; Kowol CR; Keppler BK
Chem Biodivers; 2019 Jan; 16(1):e1800520. PubMed ID: 30566287
[TBL] [Abstract][Full Text] [Related]
8. Supramolecular assembly of isomeric SN-38 prodrugs regulated by conjugation sites.
Tang Z; Zhang J; Li W; Wen K; Gu Z; Zhou D; Su H
J Mater Chem B; 2024 Jun; 12(25):6146-6154. PubMed ID: 38842181
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
10. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
11. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy.
Gong Y; Chen M; Tan Y; Shen J; Jin Q; Deng W; Sun J; Wang C; Liu Z; Chen Q
ACS Appl Mater Interfaces; 2020 Nov; 12(45):50248-50259. PubMed ID: 33135879
[TBL] [Abstract][Full Text] [Related]
12. SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy.
Huang Y; Wang L; Cheng Z; Yang B; Yu J; Chen Y; Lu W
J Control Release; 2021 Nov; 339():297-306. PubMed ID: 34619226
[TBL] [Abstract][Full Text] [Related]
13. Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy.
Zhang Y; Wang J; Liu C; Xing H; Jiang Y; Li X
J Mater Chem B; 2023 Mar; 11(11):2478-2489. PubMed ID: 36843543
[TBL] [Abstract][Full Text] [Related]
14. Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer.
Xu C; Xu J; Zheng Y; Fang Q; Lv X; Wang X; Tang R
J Mater Chem B; 2020 Apr; 8(13):2726-2737. PubMed ID: 32154530
[TBL] [Abstract][Full Text] [Related]
15. Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins.
Chowdhury MA; Moya IA; Bhilocha S; McMillan CC; Vigliarolo BG; Zehbe I; Phenix CP
J Med Chem; 2014 Jul; 57(14):6092-104. PubMed ID: 24940640
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 4-thiazolidinone derivatives with promising anti-breast cancer activity: Synthesis, characterization, in vitro and in vivo results.
Tahmasvand R; Bayat P; Vahdaniparast SM; Dehghani S; Kooshafar Z; Khaleghi S; Almasirad A; Salimi M
Bioorg Chem; 2020 Nov; 104():104276. PubMed ID: 32992280
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
18. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.
Huang B; Desai A; Tang S; Thomas TP; Baker JR
Org Lett; 2010 Apr; 12(7):1384-7. PubMed ID: 20192275
[TBL] [Abstract][Full Text] [Related]
19. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.
Zheng S; Wang J; Ding N; Chen W; Chen H; Xue M; Chen F; Ni J; Wang Z; Lin Z; Jiang H; Liu X; Wang L
J Nanobiotechnology; 2021 Nov; 19(1):381. PubMed ID: 34802453
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
